PYPD (PolyPid Ltd) Market Value to Book Value Ratio

Official company branding of polypid.com (PYPD)

PolyPid Ltd. (PYPD) specializes in developing anti-pathogen solutions. The asset's price trajectory at the 19.81 level correlates with the implementation results of the PLEX system and the pace of regulatory drug approvals. The company is currently transitioning to the commercialization of its developments in the US by establishing distribution channels. Business growth relies on close collaboration with surgical centers to conduct joint trials.

PYPD polypid.com: Market Value to Book Value in the range 07/04/2022 - 10/27/2026

Financial and market metric breakdowns for PolyPid Ltd. (PYPD)

- price and consensus price forecast:
Stock Price polypid.com|PYPD - Broker Consensus Forecast
- market capitalization data:
Market Value PolyPid Limited|PYPD - Full Business Value
- book capitalization data:
Book Value per Share PolyPid|PYPD - Accounting Value of Company|Market Capitalization to Book Value Ratio polypid.com|PYPD - Company Total Assets
- debt and liquidity data:
Debt to Equity PolyPid Ltd.|PYPD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity polypid.com|PYPD - Company Total Debt|Debts to Book Capitalization PolyPid Limited
Initial company analysis:PolyPid Ltd - PYPD
Original product of polypid.com

PolyPid Ltd. (PYPD) maintains a high reputation in the field of antibiotic prophylaxis, which creates significant intangible business value. This metric compares the company's current market value with its net assets, revealing the market premium over capital. This premium reflects investor confidence in management efficiency and future earnings. However, rising operating expenses could quickly erode this gap. The dynamics of this relationship are demonstrated by the market-to-book capitalization ratio.

Main competitors

Market Capitalization to Book Value Ratio Summit Therapeutics|MRNA (modernatx.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Vaxcyte PCVX|Market Capitalization to Net Assets Tarsus Pharmaceuticals Inc|CorMedix Corp (CRMD) - Market Capitalization to Book Value Ratio|Market Value to Book Value Seres Therapeutics, Inc (MCRB)|Market Capitalization to Book Value Ratio SPRO (Spero Therapeutics)|SCYNEXIS Inc - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio AN2 Bio (ANTX)|LSB: Market Value to Book Value|ITRM (iterumtx.com) - Market Value to Book Value Ratio|BiomX (PHGE) - Market Cap to Net Assets Ratio|SNGX (Soligenix Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio 60 Degrees Pharma (SXTP)|Oragenics, Inc. (OGEN) - Market Cap to Net Assets Ratio|Market Value to Book Value Onconetix Inc (ONCO)|Market Capitalization to Book Value Ratio OPGN